IDH-specific vaccine for high-grade gliomas

IDH-specific vaccine for high-grade gliomas

VJOncology

1 year
492 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The NOA-16 trial is a multicenter, Phase I trial, which enrolled patients with newly diagnosed grade III and IV astrocytomas with specific IDH mutations. Here, Wolfgang Wick, MD, of the German Cancer Research Center, Heidelberg, Germany, speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, provides an overview of this trial, explaining how the IDH-specific vaccine tested will be integrated into the first-line treatment of these patients. The immunogenicity of the vaccine in the blood and tumors of the patients after treatment was assessed, and further investigations will now be carried out to detect the specific immune responses occuring when this treatment is combined with the immune checkpoint inhibitor avelumab.
Up Next Autoplay
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
Category: Brain Cancer
2 Views
alexvarney 20 hours
Predicting Tumor Recurrence: How Does This Help Us?
Predicting Tumor Recurrence: How Does This Help Us?
Category: Brain Cancer
4 Views
Baylor College of Medicine 4 weeks
Predicting Tumor Recurrence
Predicting Tumor Recurrence
Category: Brain Cancer
17 Views
Baylor College of Medicine 4 weeks
How does this affect clinicians today?
How does this affect clinicians today?
Category: Brain Cancer
6 Views
Cleveland Clinic 2 months
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
Category: Brain Cancer
14 Views
Cleveland Clinic 2 months
Oncoceutics Commemorates National Childhood Cancer Awareness Month
Oncoceutics Commemorates National Childhood Cancer Awareness Month
Category: Brain Cancer
14 Views
alexvarney 2 months
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Category: Brain Cancer
19 Views
alexvarney 2 months
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Category: Brain Cancer
36 Views
alexvarney 2 months
Why Does This Subset Of Patients Respond To ONC201: It Appears To Be Very Effective In This Subset Of The Disease Because Its A Vulnerability Produced By This Mutation
Why Does This Subset Of Patients Respond To ONC201: It Appears To Be Very Effective In This Subset Of The Disease Because Its A Vulnerability Produced By This Mutation
Category: Brain Cancer
155 Views
Annual-Meeting 5 months
Other Suitable Combinations For This Agent That Could Help More People: Which Combination Makes The Most Sense For A Given Patient Will Depend On What Is Happening In Their Tumor
Other Suitable Combinations For This Agent That Could Help More People: Which Combination Makes The Most Sense For A Given Patient Will Depend On What Is Happening In Their Tumor
Category: Brain Cancer
114 Views
Annual-Meeting 5 months